Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

Regeneron Pharmaceuticals is viewed favorably because its fundamentals are anchored by a diversified commercial portfolio led by Dupixent and the Eylea franchise, while its fully integrated biopharmaceutical R&D engine and antibody/receptor-fusion expertise continue to generate multiple shots on goal across eye disease, immunology, oncology, and other serious diseases. The company also benefits from meaningful strategic partnerships with Sanofi and Bayer, which help expand its commercial reach and support development economics, and it maintains shareholder support through a $3.4B buyback, while its balance of marketed products and pipeline assets provides multiple avenues for medium-term growth even as some programs face clinical risk. Near-term headwinds such as Eylea erosion, Dupixent life-cycle uncertainty, and the fianlimab phase III miss temper upside in the immediate future, but the long-term outlook remains constructive because high-dose aflibercept conversion, new Dupixent indications, and pipeline catalysts like the Eylea HD pre-filled syringe approval expected this qtr and the 4Q26 cemdisiran gMG PDUFA could help offset competitive pressure and sustain earnings power.

Regeneron Pharmaceuticals is facing a negative fundamental setup because Eylea remains exposed to erosion from biosimilars and competitors, which could compress revenue ahead of biosimilar entry and weaken one of the company’s most important ophthalmology franchises. At the same time, the company’s outlook is clouded by recent pipeline setbacks and meaningful clinical development and regulatory risks across oncology and other programs, leaving it dependent on a relatively sparse near-term catalyst calendar with major readouts concentrated in 2026 and beyond. Although Dupixent still benefits from entrenched market position, positive real-world experience, and comfort in self-administration, emerging competition in atopic dermatitis from next-generation biologics and oral therapies, along with EUR/USD headwinds and US drug pricing policy, could slow reported growth and pressure overall fundamentals.